https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:12771 43 and >48) and ‘impaired’ functioning (defined as a score of ≤43 and ≤48), respectively. Psychological variables were assessed via valid self-report. Results: Having ‘more’ versus ‘less’ severe abdominal pain (OR = 9.41; 95% CI 1.17–75.43, P = 0.03) and ‘more’ versus ‘less’ frequent diarrhoea (OR = 2.19; 95% CI 1.13–4.26, P = 0.02) along with increasing age (OR = 1.03; 95% CI 1.01–1.05, P = 0.003) were significant independent predictors of having impairment in physical functioning. In terms of psychological factors, having higher levels of depression (OR = 1.61; 95% CI 1.36–1.91) and somatic distress (OR = 1.17; 95% CI 1.09–1.27) were independently associated with mental and physical impairment, respectively. Conclusion: The current frequency and severity threshold cut-offs for IBS symptoms in the Rome III criteria are associated with a clinically meaningful impairment of quality of life in community subjects with IBS.]]> Sat 24 Mar 2018 08:18:20 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:55452 4 weeks are widely lacking. We evaluated the efficacy and safety of 8 weeks of treatment with the herbal combination product STW 5-II for patients with functional dyspepsia (FD) meeting Rome II criteria. We also conducted a post hoc analysis including patients meeting Rome IV criteria for FD and evaluated the effect of the G-protein beta 3 (GNB3) subunit polymorphism (C825T) on therapeutic response. Methods: This multicenter, placebo-controlled, double-blind study included 272 FD patients meeting Rome II criteria in the intention-to-treat cohort and 266 meeting Rome IV criteria. We used the validated Gastrointestinal Symptom Score (GIS) to assess GI symptoms, defining response rate as the proportion of patients with ≥50% GIS improvement in at least three of four assessments. Results: After 8 weeks, the response rate was significantly higher in the STW 5-II group versus placebo (61.2% vs 45.1%, P = 0.008). Mean GIS non-significantly improved with STW 5-II treatment (7.9 ± 4.41 vs 6.7 ± 4.91 with placebo; P = 0.07). In the Rome IV subgroup analysis, STW 5-II yielded a better response rate (P = 0.01) versus placebo and greater postprandial distress symptom improvement (P = 0.04) versus placebo. Safety parameters did not differ between groups, and GNB3 status was not linked with therapeutic response. Conclusion: STW 5-II is efficacious, with no observed safety signals at up to 8 weeks of treatment in patients with FD meeting Rome II or IV criteria.]]> Mon 03 Jun 2024 08:38:06 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41727 Fri 12 Aug 2022 10:04:18 AEST ]]>